Moderna, Inc. (MRNA)

NASDAQ · Health Care · market cap 25.28B

Share price

$158.07

At the last nightly close

Intrinsic value

n/a

No valuation the available data can support for this company.

Margin of safety

n/a

Requires an intrinsic value and a price.

EV / EBIT

n/a

Not ranked: negative ebit.

How these numbers are computed

The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above is the low end of what they agree on.

The frame gives no credit for growth. A company that compounds will therefore read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.

The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.

Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-08-23.

Key metrics

Price / earningsn/a
Price / book9.3
EV / EBITDA-24.7
FCF / EVn/a
Return on equity-39.0%
Return on assets-13.3%
Debt / equity0.19
Gross margin-66.0%

Market position

52-week high$174.38
52-week low$22.36
From 52-week high-9.4%
RSI (14)66.0
200-day moving average$67.44

Annual financials

PeriodRevenueOperating incomeNet incomeEPSFree cash flow
2025-FY1.92B-3.07B-2.82B-7.26-2.08B
2024-FY3.20B-3.94B-3.56B-9.28-4.05B
2023-FY6.75B-4.24B-4.71B-12.33-3.83B
2022-FY18.88B9.42B8.36B21.264.58B
2021-FY18.47B13.30B12.20B28.2913.34B

Filed figures from SEC EDGAR, in the reporting currency.

Next earnings

Q4 2026 expectedNovember 5, 2026
Consensus EPS estimate-1.29

Recent news

The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on MRNA.

Run the board on MRNA

10 free analyses · no signup, no card

This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.